You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Clinical and laboratorial characteristics of HIV-1 co-infected leishmaniasis patients and control groups.

From: High levels of T lymphocyte activation in Leishmania-HIV-1 co-infected individuals despite low HIV viral load

Parameters AVL/HIV-1 patients (n = 9) ATL/HIV-1 patients (n = 8) HIV-1 infected* (n = 16) Healthy subjects (n = 8)
Age, years, (median) 38 (35-50)a 44 (38-54)b 39 (33-49)c 26 (25-30)abc
Male sex, n, (%) 9 (100)d 8 (100)e 15 (94)f 4 (50)def
CD4+T Cell count, cells/mm3 62 (52-127)g 404 (294-597)h 380 (223-450)i 1,106 (957-1,300)ghi
Current AIDS diagnosis, Number of cases (%) 9 (100) 6 (75) 8 (50) ----
Time of clinical remission of leishmaniasis, months 8 (6-12) 11 (7.5-14) ---- ----
Patients with undetectable viremia, (%) 5 (55.6) 4 (50) 9 (56.2) ----
Viral load levels of patients with detectable viremia, copies/mL 142,240 (24,025-279,321) 6,200 (2,012-78,176) 12,010 (2,000-136,625) ----
  1. N = number, AVL - American visceral leishmaniasis, ATL - American tegumentary leishmaniasis *HIV-1 infected patients without leishmaniasis Note: Data are median (interquartile range) values, except for current AIDS diagnosis.
  2. Patients × Health subjects (a - p < 0.001; b/c - p < 0.01; d/e/f × def - p < 0.05), g/h/i × ghi - p < 0.001; g × h - p < 0.01; g × i - p < 0.01